Bust #9: The 'You May Be Entitled' Ad, Slowed Down

🎬 Bust #9 · The Commercial As You See It

An Alarm Bell, A Deep Voice, And A Cash Award

Today's bust does not sing. It alarms. The screen flashes a warning. A grave voice lowers the lights with its tone alone: “Attention! If you or a loved one took this medicine and suffered… you may be entitled to a cash award. Time to file is limited — call now.”

In thirty seconds you get a scary list of harms, a drumbeat of urgency, and the warm suggestion that a pot of money is sitting with your name on it. What you do not get, at any speed a human can follow, is the rest of the story: how common or rare the risk in question actually is, whether the medicine was ever recalled, who is really paying for this ad, or what “may be entitled” quietly leaves out.

To be fair from the very start: people who are genuinely harmed can have real legal claims, and truthful lawyer advertising is allowed. The Federal Trade Commission itself says it has opposed overly broad restrictions on truthful, non-misleading information. The bust today is not “lawsuits are fake.” The bust is a specific style the FTC has formally warned about — an ad dressed up like an official medical alert, racing past risk context at auctioneer speed. Today we slow that style waaay down, using the FTC's own letters as our script.

🔍 The Fine Print, Slowed Waaay Down

What “You May Be Entitled” Actually Says, At Walking Pace

• “Attention! Drug warning!” The FTC's September 2019 letters flag exactly this opening. Lawsuit ads that open with sensational warnings or alerts, the agency says, may initially mislead viewers into thinking they are watching a government-sanctioned medical alert or public service announcement. The FTC's reminder is simple: an ad promoting a service should be identifiable as advertising from the beginning — not costumed as an official warning.
• “Your medicine has been linked to terrible harms.” Slowed down, the FTC's concern is about proportion. In one letter, about ads naming several type 2 diabetes medicines, the agency noted the FDA describes one infection named in the ad as a rare side effect — so implying a substantial risk appeared to be false without solid evidence. In another, about a mental-health medicine and uncontrollable gambling, the FDA had likewise called the reported problems rare. “Linked to” in a loud voice is not the same sentence as “common,” “proven,” or “likely for you” — and the ad rarely pauses to say which one it means.
• “It sounds like the drug was recalled.” That impression is the FTC's headline worry. Its press release says some lawsuit ads may misrepresent risks and could leave consumers with the false impression that their physician-prescribed medication has been recalled. A lawsuit being advertised is not a recall. A warning letter is not a recall. If a medicine had actually been recalled, that would be its own FDA announcement — not a feeling left behind by dramatic music.
• “You may be entitled to a cash award.” Listen to the little word doing all the heavy lifting: may. The FTC says advertisers must have competent and reliable scientific evidence to substantiate claims about purported risks, and its letters press the same point claim by claim. “May” promises nothing — no finding that a claim is valid, no amount, no timeline, no outcome. It is an invitation to call a law firm or a lead generator, which is the one part of the ad that is exactly what it appears to be.
• “Time to file is limited.” Deadlines for legal claims can be real, and only an attorney who knows the facts and the jurisdiction can explain one. What the FTC objected to was never the existence of a deadline — it was ads using urgency and alarm before a viewer could tell an advertisement from a medical alert, or a rare risk from a common one.
• The line almost no version of this ad says out loud. The FTC's letters suggest lawsuit ads may need a clear and prominent disclosure, in both audio and visual form, stating that viewers should not stop taking their medications without first consulting their doctors. The reason is not paperwork. It is the next section — and it is the most serious paragraph in this entire post.

None of this is us deciding any claim, for any person, about any medicine. It is the FTC's own 2019 press release and its own warning letters, read at normal speed — which is all this blog ever does.

🧠 What The Song Doesn't Spell Out

The Recall That Wasn't, The Risk Without A Denominator, And The Stopped Pill

1. The scariest harm in the FTC's file was not in the ad's list. It was what viewers did after the ad. The FTC's letters note that the FDA's Adverse Event Reporting System contains reports of consumers who saw lawsuit ads about the prescription drugs they were taking, discontinued those medications, and suffered adverse consequences as a result. The letters say an ad that causes, or is likely to cause, viewers to discontinue their medications might constitute an unfair act or practice. Slowed down, that is the whole bust in one sentence: an ad about a possible harm can create a real harm if it frightens someone into quitting a prescribed medicine cold, without a doctor in the conversation.

2. A risk without a rate is just a mood. The FTC reviewed ads about, among others, blood thinners and drugs for diabetes, acid reflux, and high blood pressure. Its recurring question was evidentiary: does the advertiser actually have competent and reliable scientific evidence for the size of risk the ad implies? A list of severe outcomes, read in a grave voice over red graphics, tells you an outcome has been reported or alleged. It does not tell you how often it happens, in whom, compared with what, or against what benefit the medicine was prescribed to provide. Those missing denominators are not fine print. They are the difference between information and atmosphere.

3. “Some” is the FTC's word — and it matters in both directions. The agency sent letters to seven legal practitioners and lead generators, did not publicly identify who received them in its press release, and wrote about some ads that may be deceptive or unfair. That is a regulator expressing documented concerns and promising to keep monitoring and take follow-up action as warranted — not a blanket verdict that every lawsuit ad, every firm, or every underlying claim is bogus. Fairness cuts this way too: a well-founded claim, presented truthfully, is not busted by anything here. What is busted is the costume, the speed, and the missing context.

4. The sponsor is part of the message. Some of these spots are placed by lead generators — companies whose job is to collect potential clients — rather than by the law firm a caller may eventually speak with. The FTC addressed its letters to practitioners and lead generators for a reason. When the first voice you hear belongs to a marketing pipeline, “call now” is not neutral information. It is the product being sold: your call.

⚖️ The Busters Verdict

Verdict: A Real Right, Sold Like A Fire Alarm

Is “you may be entitled” ever true? Slowed down, the honest answer is: sometimes, for some people, as decided through a legal process on specific facts — never by a TV spot, and never at the speed of one. The FTC's documented worries are narrower and more useful than cynicism: an ad should look like an ad from the first second, a risk should come with its evidence and its rarity, a lawsuit should never masquerade as a recall, and no commercial should ever be the reason someone stops a prescribed medicine without calling their doctor. The ad sells the alarm. The fine print owns the context.

So here is your Commercial Busters homework — the questions worth taking to a qualified professional, a doctor about medicines and an attorney about claims, because they can see your situation and we cannot:

• “Doctor, is this medicine actually recalled, or is what I saw an advertisement for lawsuits?”
• “How common or rare is the risk the ad named, for someone in my situation — and what benefit is this medicine prescribed to provide me?”
• “What would happen if I stopped this medicine suddenly, and is there any change we should make together instead?”
• “Attorney, who is sponsoring this ad — your firm, or a lead generator — and what evidence would a claim like mine actually require?”
• “What does ‘may be entitled’ mean in documented terms: what has to be proven, by whom, and by what real deadline in my jurisdiction?”

Sources you can check yourself: Federal Trade Commission, press release “FTC Flags Potentially Unlawful TV Ads for Prescription Drug Lawsuits” (September 24, 2019) — letters to seven legal practitioners and lead generators, the false recall impression, claims about blood thinners and drugs for diabetes, acid reflux, and high blood pressure, the competent-and-reliable-evidence standard, reports of consumers who discontinued medicines after seeing ads, and sensational openings that can look like government-sanctioned medical alerts: ftc.gov — lawsuit ads press release. Federal Trade Commission, warning letters regarding prescription drug lawsuit TV ads (September 19, 2019) — the claim-by-claim letters, including the diabetes-medicine, mental-health-medicine, and leukemia-drug examples, the FDA's “rare” characterizations, and the suggested clear audio and visual disclosure not to stop a medicine without a doctor: ftc.gov — warning letters (PDF).

Final reminder: This post is for educational and entertainment purposes only. It is not medical, financial, legal, insurance, or any other professional advice, and it should not be used to make any kind of decision. Talk to a qualified professional about your own situation. Please do not contact us about the products, drugs, policies, or services covered here — we do not provide advice on any of them.